0.2890EUR-0.69%Mkt Cap: 12.94M EURP/E: 14.45Last update: 2026-05-14
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)14.45
P/E (Forward)0.45
PEG—
P/B5.35
P/S616.01
EV/EBITDA-7.39
EV/Revenue534.68
EPS (TTM)0.02
EPS (Forward)0.64
Cash Flow & Leverage
FCF Yield-8.18%
FCF Margin-5038.69%
Operating CF-6.90M EUR
CapEx (TTM)—
Net Debt/EBITDA1.12
Net Debt-1.71M EUR
Technical
SMA 500.3174 (-8.9%)
SMA 2000.2705 (+6.8%)
Beta1.19
S&P 52W Chg24.23%
Avg Vol (30d)15.48K
Avg Vol (10d)15.13K
Technical Indicators
RSI (14)40.7
MACD-0.0074
MACD Signal-0.0048
MACD Hist.-0.0026
BB Upper0.3349 EUR
BB Middle0.3095 EUR
BB Lower0.2842 EUR
BB Width16.40%
ATR (14)0.0171 EUR
Vol Ratio (20d)0.86x
52W Range
0.160026% of range0.6500
52W High0.6500 EUR
52W Low0.1600 EUR
Profitability
Gross Margin61.90%
EBITDA Margin0.00%
Profit Margin3952.38%
Oper. Margin30414.28%
ROE34.06%
ROA19.31%
Revenue Growth-95.90%
Earnings Growth—
Balance Sheet
Debt/Equity0.00
Current Ratio1.92
Quick Ratio1.38
Book Value/Sh0.0540 EUR
Cash/Share0.0380 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.44.76M
Float14.15M
Insiders10.78%
Institutions58.59%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap12.94M EUR
Enterprise Value11.23M EUR
Revenue (TTM)21.00K EUR
Gross Profit13.00K EUR
Net Income (TTM)830.00K EUR
Revenue/Share0.0000 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees4
Last Price0.2890 EUR
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINUS1512052002